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Abstract
Background: Despite recent improvements in the burden of cardiovascular disease (CVD) in the UK, deaths from CVD
are relatively high compared with other high-income countries. An estimated 7 million people in the UK are living with
CVD, and the healthcare cost is approximately £11 billion annually. In more than 90% of cases, the risk of a first heart
attack is thought to be related to modifiable risk factors including smoking, poor diet, lipidemia, high blood pressure,
inactivity, obesity and excess alcohol consumption. The aim of the study is to synthesise evidence for the comparative
effectiveness and cost-effectiveness of different interventions for the primary prevention of CVD.
Methods: We will systematically search databases (for example, MEDLINE (Ovid), Embase (Ovid), Cochrane Library) and
the reference lists of previous systematic reviews for randomised controlled trials that assess the effectiveness and cost-
effectiveness of any form of intervention aimed at adult populations for the primary prevention of CVD, including but
not limited to lipid lowering medications, blood pressure lowering medications, antiplatelet agents, nutritional
supplements, dietary interventions, health promotion programmes, physical activity interventions or structural and policy
interventions. Interventions may or may not be targeted at high-risk groups. Publications from any year will be
considered for inclusion. The primary outcome will be all cause mortality. Secondary outcomes will be
cardiovascular diseases related mortality, major cardiovascular events, coronary heart disease, incremental costs
per quality-adjusted life years gained. If data permits, we will use network meta-analysis to compare and rank
effectiveness of different interventions, and test effect modification of intervention effectiveness using
subgroup analyses and meta-regression analyses.
Discussion: The results will be important for policymakers when making decisions between multiple possible
alternative strategies to prevent CVD. Compared to results from existing multiple separate pairwise meta-analyses, this
overarching synthesis of all relevant work will enhance decision-making. The findings will be crucial to inform
evidence-based priorities and guidelines for policies and planning prevention strategies of CVD.
Systematic review registration: PROSPERO CRD42019123940.
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Background
Cardiovascular disease (CVD) includes all the diseases of
the heart and circulation including coronary heart dis-
ease (CHD) and stroke. CVD accounts for the highest
proportion of non-communicable disease deaths, result-
ing in 160,000 deaths in the UK annually [1–3]. Cardio-
vascular risk is determined by a variety of ‘upstream’
factors (such as healthy food production and availability,
access to a safe environment that encourages physical
activity and access to health education) as well as ‘down-
stream’ behavioural issues (such as unhealthy diet,
smoking and physical inactivity). In more than 90% of
cases, the risk of a first heart attack is related to nine
potentially modifiable risk factors [4, 5]: smoking/to-
bacco use, poor diet, high blood cholesterol, high blood
pressure, high blood glucose, insufficient physical activ-
ity, overweight/obesity, diabetes, psychosocial stress and
excess alcohol consumption. A significant proportion of
CVD morbidity and mortality can be prevented through
population strategies for primary prevention. There is a
major potential population health impact of improving
our understanding of CVD prevention.
Though there are many pairwise systematic reviews
and meta-analyses that have examined the effectiveness
of drug, lifestyle and policy/structural interventions
either separately and collectively (Additional file 1); there
is no systematic review to date that has comprehensively
synthesised all available evidence to understand the
comparative effectiveness of these interventions for the
primary prevention of CVD with the aim of supporting
evidence-based recommendations to policymakers. The
overarching aim of the proposed study is to fill this re-
search gap by synthesising evidence for the comparative
effectiveness of different interventions for the primary
prevention of CVD using a network meta-analysis. The
specific objectives are as follows: (1) to use comprehen-
sive searches and to describe the scale and range of in-
terventions that have been conducted and to categorise
interventions and their components, (2) to determine
which interventions, have the greatest probability of effect-
iveness for the primary prevention of CVD (see Fig. 1), (3)
to identify which intervention components are associated
with the greatest effectiveness for the primary prevention
of CVD, (4) to examine reliability and conclusiveness of
the available evidence on interventions for the primary
prevention of CVD and to identify the areas with most po-
tential benefit for future research, (5) to identify trial char-
acteristics associated with prevention effect estimates, (6)
to identify, appraise and synthesise any published eco-
nomic evaluations and economic models of interventions
for the primary prevention of CVD and (7) to determine
the applicability and generalisability of interventions and
the assessments of their cost-effectiveness to the UK NHS
setting.
Methods
The present protocol has been registered within the PROS-
PERO database (registration number CRD420119123940)
and is reported in accordance with the Preferred Reporting
Items for Systematic review and Meta-Analysis Protocols
(PRISMA-P) checklist [6], and the PRISMA extension
statement for reporting of systematic reviews incorporating
network meta-analyses of healthcare interventions [7] (see
checklist in Additional file 2). The record in PROSPERO
and subsequent publications will be updated with any
amendment made to the protocol.
Fig. 1 Analytic framework Note: pathway 1 will be systematically reviewed (in green), while pathways 2, 3 and 4 will not be reviewed (in red)
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Eligibility criteria
We will evaluate each identified study against the follow-
ing selection criteria:
Study population: adult populations (≥18 years of age)
included in population-based studies, which may or may
not be targeted at moderate/high CVD risk groups (such
as hypertension, obesity, hyperlipidaemia, type 2 diabetes
or a combination of these). As the review focuses on the
primary prevention of CVD, we will exclude trials that
included those who have experienced a previous myo-
cardial infarction (MI), stroke, revascularisation proced-
ure (coronary artery bypass grafting (CABG) or per
cutaneous transluminal coronary angioplasty (PTCA)),
and those with angina or angiographically defined cor-
onary heart disease (CHD). Studies with mixed popula-
tions, i.e. both population with and without CVD will be
included if data for the relevant primary prevention can
be extracted.
Intervention: any form of intervention aimed at the
primary prevention of CVD, including but not limited to
drugs (lipid lowering medications, blood pressure lower-
ing medications, antiplatelet agents), diet (nutritional
supplements, dietary interventions), physical activity or
public health (health promotion programmes, structural
and policy interventions) (Table 1).
Comparators: other forms of intervention (such as a
minimal intervention, active intervention, concomitant
intervention), placebo, usual care or no intervention
control group or wait list control.
Outcome measures: The primary outcome will be all
cause mortality. Secondary outcomes will be cardiovas-
cular diseases related mortality, major cardiovascular
events (defined as fatal and non-fatal myocardial infarc-
tion, sudden cardiac death, revascularisation, fatal and
non-fatal stroke and fatal and non-fatal heart failure),
coronary heart disease (fatal and non-fatal myocardial
infarction and sudden cardiac death, excluding silent
myocardial infarction), incremental costs per quality-
adjusted life years gained reported alongside a rando-
mised trial.
Study design: randomised controlled trials (RCTs) of
at least 6 months’ duration of follow-up. Units of ran-
domisation could be either individuals or clusters (such
as family, workplace).
Information sources and search strategy
Clinical effectiveness
Due to the likelihood of a high volume of relevant trials
to be included, we will follow standard guidelines for in-
tegrating existing systematic reviews into new reviews
[8, 9]. Where existing systematic reviews with acceptable
search and study selection methods (especially Cochrane
reviews) are available for any of the intervention
categories, these will be used as a starting point to iden-
tify relevant studies. Initial searches for relevant system-
atic reviews will not be restricted by date. Searches will
not be restricted by language.
a) A comprehensive literature search for existing sys-
tematic reviews will be developed iteratively and under-
taken in major medical and health-related electronic
bibliographic databases including MEDLINE (Ovid),
Embase (Ovid), Cochrane Database of Systematic Re-
views (Wiley) and DARE (CRD). Systematic reviews that
potentially include primary studies meeting our inclu-
sion criteria will be selected. Records for the included
(and, if available, excluded) studies in all selected sys-
tematic reviews will be identified and imported into
EndNote using HubMed Citation Finder [10], systemat-
ically de-duplicated and screened.
The most recent systematic review for any interven-
tion or intervention category will be assessed using
AMSTAR-2 [11] items 4, 5 and 7 to help determine
whether or not the search and study identification
methods are acceptable for the purpose of identifying
studies for this network meta-analysis. If not, the next
most recent review where available will be assessed using
the same criteria. An analysis of the search dates of the
chosen reviews will inform the date limit used for the
search for more recent trials (i.e. those that are not yet
included in a published review). The aim of this is to en-
sure all time periods are covered.
b) The search for recent trials will be developed itera-
tively and will be informed by records of a broad cross-
section of known studies. Searching based on the concepts
of prevention and CVD outcomes, or on intervention
terms and CVD outcomes, will be considered and tested.
Scoping searches have retrieved very high numbers of tri-
als in Cochrane Controlled Register of Trials (CENTRAL)
(Wiley) using either approach. Our trial search will focus
on CENTRAL (Wiley). For any interventions where no ac-
ceptable systematic review is available, a search for trials
with no date limit and including relevant intervention
terms will be performed. A draft search strategy in CEN-
TRAL (Wiley) is available in Additional file 3.
c) In order to capture studies with more obscure re-
cords and those that may have been excluded by previ-
ous systematic reviews, we will run a highly sensitive
search with no date limit and use machine learning to
identify a proportion of these records for screening (see
‘Selection Process’ below).
d) Finally, the reference lists of included studies will be
examined for additional relevant studies.
Cost-effectiveness
We will develop searches iteratively, referring to known
articles, existing strategies and assessed search filters
[12]. Search terms will include economic, cost and
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health-related quality of life-related terms combined
with CVD terms. Other concepts may be added as ne-
cessary. Databases will include the following: MEDLINE
(Ovid), MEDLINE In-Process Citations and Daily Up-
date (Ovid) and Embase (Ovid). Searches will be limited
to studies in the English language, and to humans. We
will also check the reference lists of included studies and
any relevant reviews.
Selection process
In order to reduce the workload of screening the
searches result from the highly sensitive search with no
date limit, we will develop a bespoke classifier/algorithm
to identify potentially relevant studies. We will aim to
achieve a high-performing algorithm comparable to hu-
man screening [13]. The computer will be fed with train-
ing data using the included and excluded studies found
via our other searches. From this algorithm, the machine
can make predictions (include or exclude) on other titles
and abstracts that it has never seen. We will screen the
titles/abstracts of a small proportion 10% of these results.
Data collection process
Data will be independently extracted using a pre-specified
piloted proforma by two reviewers, with discrepancies
resolved by a third reviewer. We will use a data collection
form for study characteristics and outcome data. One
author will extract study characteristics from the included
studies and a second author will spot-checked study char-
acteristics for accuracy against the trial report. Any incon-
sistencies will be resolved by discussion.
We will extract the following characteristics:
Study citation: year(s) of study, registration number to
trial registries, year of publication, location, setting,
number of centres, sample size, diagnostic criteria, fund-
ing/sponsor
Methods: including study design (type of RCT), num-
ber of arms, risk of bias (see below)
Participants: number, mean age, age range, gender, se-
verity of condition, diagnostic criteria, baseline measures
of physiological functioning (e.g. cardiovascular function,
blood pressure, body mass index, blood glucose, HbA1C,
smoking history), inclusion and exclusion criteria
Table 1 Health technologies (interventions)
Pharmacologic interventions
Lipid lowering medications Blood pressure lowering medications Nutritional supplements Others
Atorvastatin
Fluvastatin
Lovastatin
Pitavastatin
Pravastatin
Rosuvastatin
Fenofibrate
Bezafibrate
Ezetimibe
ACE inhibitors
Angiotensin receptor blockers (ARBs)
Calcium channel blockers
Thiazide diuretics
Adrenergic receptor antagonists
(alpha and beta blockers)
Vasodilators
Renin inhibitors
Vitamin D, E, K and multivitamins
Niacin
Omega 3 and fatty acids
Anti-oxidants
Calcium
Co-enzyme Q10
Selenium
Folic acid
Garlic
Fixed dose combinations
‘polypill’
Antiplatelet agent (Aspirin)
Lifestyle-modification interventions
Dietary interventions Health promotion Exercise/physical activity in general
Mediterranean diet
Fibres
Nut consumption
Chocolate
Fruits and vegetables
Green and black tea
Reduced salt intake
Reduced fat intake
Smoking cessation
Weight reduction
Reduction in alcohol intake
Multiple risk factors intervention
Digital health promotion
Endurance (or aerobic) exercise
Strengthening exercise
Balance
Tai-chi
Flexibility
Yoga
Aquatic
Qiqong
Transcendental meditation
Combined exercise
Structural and policy-based
interventions (population-
wide interventions)
Taxation and subsidies
Mass media campaigns
Food and menu labelling
Local food environment
Worksite wellness programmes
Marketing restrictions
Quality standards
Healthy local environment
Addressing air pollution
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Interventions: intervention, comparison, concomitant
medications and excluded medications
Outcomes: primary and secondary outcomes specified
and collected, and time points reported including infor-
mation on whether an intention to treat approach has
been used and how it was defined
Data items and measurement of treatment effect
Clinical effectiveness
We will report dichotomous outcomes as risk ratios
(RRs). For continuous outcomes, we will calculate mean
differences (MDs) when the studies report homogenous
outcomes. Time-to-event outcomes or generic inverse
variance outcomes will be expressed as the logarithm of
hazard ratio (HR).
If possible, we will use the intention-to-treat popula-
tion for all analyses. When effect sizes are incompletely
reported, we will contact the corresponding author.
When the SDs of absolute changes from baseline are not
available from individual trials, we will impute them as
described in detail in the Cochrane Handbook [14]. In
brief, we will assume a correlation of r = 0.5 between
baseline and follow-up to estimate SD for change from
baseline. Using the imputed correlation coefficient
values, we will calculate SDs for the change from base-
line for the studies with missing SDs using the following
formula:
SDchange ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SD2baseline þ SD2final− 2rSDbaselineSDfinalð Þ
q
We will include cluster-randomised trials in the meta-
analysis along with individually randomised trials (unit
of analysis issues). Cluster-randomised trials will be la-
belled with a (C). For cluster-randomised trials to be in-
cluded in the network meta-analyses, we will adjust for
design effect using an ‘approximation method’ [15] if the
trial did not use a cluster-adjusting analytical strategy.
The ‘approximation method’ entails calculation of an ‘ef-
fective sample size’ for the comparison groups by divid-
ing the original sample size by the ‘design effect’, which
is 1 + (M − 1) ICC, where M is the average cluster size
and ICC is the intra-cluster correlation coefficient. For
dichotomous data, we will divide both the number of
participants and the number who experience the event
by the same design effect, while for continuous data,
only the sample size will be reduced (means and stand-
ard deviations (SDs) will be left unchanged).
Cost-effectiveness
For each identified study that meets the selection cri-
teria, we will extract the following data: country, study
design, population, intervention(s), comparator(s), type
of economic analysis, perspective, model type (structure
and key assumptions), time horizon, effectiveness data,
primary outcome, resource use and unit cost data, price
year, discounting and the results of the base-case and
sensitivity analyses. Data such as outcomes and charac-
teristics will be synthesised quantitatively, where appro-
priate or narratively. For the primary outcome, the
preferred measure will be cost per quality-adjusted life
years (QALY) gained.
Geometry of the network
A network plot will be created to describe and present
the geometry of the intervention network of compari-
sons across trials [16]. Intervention comparisons not
connected to the rest of the network will be excluded
from the network meta-analysis and describe that com-
parison separately. In the network diagram, each node
represents an intervention, and the edges represent
head-to-head comparisons between a pair of interven-
tions. The size of a node reflects the sample size for the
intervention, and the thickness of an edge reflects the
number of trials that included the comparison [16].
Risk of bias in individual studies
We will use the Cochrane Collaboration’s tool for asses-
sing risk of bias for quality assessment of the included
trials at trial level [17]. The trials were graded (unclear,
high or low risk of bias) based on sequence generation,
allocation concealment, blinding of outcome assessor,
incomplete outcome data and selective outcome report-
ing. Risk of bias for the included trials will be assessed
using the Robot Reviewer [18]. We will use the quality
assessment of economic modelling checklist developed
by Philips et al. [19] to assess the quality of the economic
evaluation studies. We will use the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
checklist [20] to assess the quality of the economic evalu-
ation studies
For cluster-randomised trials, we will assess the fol-
lowing cluster-specific risks of bias as outlined in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [14].
Recruitment bias - whether the individuals participat-
ing in the trial were blinded to the type of cluster they
were in before agreeing to participate
Baseline imbalance - whether there were differences in
baseline characteristics between the randomised groups
Loss of clusters - whether any complete clusters were
lost to follow-up and the reasons
Incorrect analysis - whether the proper statistical ana-
lysis was carried out for a cluster-randomised design
Comparability with individually randomised trials -
whether the cluster-randomisation method could have
resulted in different intervention effects than an indi-
vidually randomised trial
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When considering treatment effects, we will take into
account the risk of bias of the studies that contribute to
that outcome.
Planned methods of analysis
Characteristics of the included studies
We will produce descriptive statistics and study popula-
tion characteristics across all eligible trials, describing
the types of comparisons and other clinical or methodo-
logical variables, such as age, co-medication, country
and study follow-up period.
Pairwise meta-analyses
In the first step we will perform series of conventional
pairwise random-effects meta-analyses by combining
studies that compared the same interventions, including
the comparison between active treatments and the dif-
ferent control arms. If very few trials are available or the
requirements of network meta-analysis are not met, it
can be that network meta-analysis will not be appropri-
ate and, in this case, conventional pairwise meta-analysis
will be applied.
Assessment of heterogeneity
We will assess between-trials heterogeneity (variability
in relative treatment effects within the same treatment
comparison) using the tau-squared (the variance of the
random effects distribution). The heterogeneity variance
will be assumed common across the various treatment
comparisons (grouped by comparison type) and we will
compare the empirical distribution with predictive distri-
butions [21–23]. We will explore the potential reasons
for heterogeneity by subgroup analysis described below.
Assessment of the transitivity assumption
The transitivity assumption will be assessed by investi-
gating the distribution of clinical and methodological
variables that can act as effect modifiers across treat-
ment comparisons [24].
We will assume that patients who fulfil the inclusion
criteria are equally likely to be randomised to any of the
interventions of interest (i.e. jointly randomisable).
When additional evidence of intransitivity is lacking and
potential effect modifiers have similar distributions
across the included studies, network meta-analysis is
likely to give valid results.
Network meta-analysis
We will conduct network meta-analyses [25, 26] to com-
pare effectiveness of the different types of interventions
for primary prevention of CVD. Given the substantial
number of interventions and the limited evidence base
available to construct the network of evidence, (in terms
of both the number of trials and the number of direct
comparisons between active interventions), we will use a
two-level hierarchical network meta-analysis to borrow
strength within the classes of intervention, strengthening
inferences and potentially reducing the uncertainty
around individual intervention effects. This will conse-
quently increase our ability to rank these and to inform
decision-making frameworks [27]. The two-level hier-
archical network meta-analysis (level 1: intervention type
and level 2: intervention class) will incorporate ex-
changeability between interventions of the same class to
predict an effect estimate for each of the interventions
individually [27].
We will calculate the probability of a given interven-
tion having the largest beneficial effects as the propor-
tion of simulations in which that intervention will be
ranked as the ‘best’ according to the relative prevention
effect estimate. In addition, we will calculate alternative
rankings (second and third best, etc.) because in some
policy and practice areas, the best intervention might be
unavailable, too costly or contraindicated. Probability
values will be summarised and reported as surface under
the cumulative ranking (SUCRA) and graphically ranked
using rankograms. SUCRA = 1 if an intervention always
ranks first and SUCRA = 0 if it always ranks last.
All the network meta-analyses analyses [25, 26] will be
conducted using a Markov chain Monte Carlo method.
The models will account for the correlation between
prevention effect estimates induced by three or more
arm trials using the multi-arm trial code. At least two
Markov chains will be run simultaneously using different
arbitrary initial values. Convergence to a stable solution
will be checked by viewing plots of the sampled simula-
tions and using the Brooks-Gelman-Rubin diagnostic
tool. All results will be reported as posterior medians of
prevention effect estimate with corresponding 95% cred-
ible intervals (CrIs). Credible intervals are the Bayesian
equivalent of classical confidence intervals. A 95% CrI
can be interpreted as a 95% probability that the param-
eter takes a value in the specified range.
Assessment of inconsistency
The evaluation of transitivity will be supplemented with
a statistical evaluation of consistency, the agreement be-
tween direct and indirect evidence. We will evaluate
consistencies between direct and indirect comparisons
in the network of evidence using the method of ‘node-
splitting’ [28], by calculating the difference for each pair
of interventions and the probability of whether direct es-
timates surpass the indirect estimate.
Investigation of heterogeneity and inconsistency
We anticipate several sources of heterogeneity relating
to the content of the intervention and study design. We
will test effect modification of intervention effectiveness
Uthman et al. Systematic Reviews           (2020) 9:105 Page 6 of 9
using subgroup analyses and meta-regression analyses.
For example, where there are sufficient data, we will
stratify our analyses (subgroup) by the following: popula-
tion risk groups (healthy versus high-risk), trial period
(older versus recent), sex (male versus female) and age
(young adult versus elderly population), by intervention
components and by characteristics of outcome measures.
Meta-regression analyses will be used to explore compo-
nents of interventions, participant characteristics and out-
come measure characteristics that can predict prevention
effect estimates within and across different types of inter-
ventions. The network meta-regression will be performed
by allowing for a common treatment-covariate interaction
for each intervention in the network meta-analysis [29].
Publication bias
To assess small study effects and publication bias, we
will use funnel plots of pairwise meta-analyses if 10 or
more studies are included. We will also use a
comparison-adjusted funnel plot for relative treatment
effects between all active and control interventions [30].
Systematic review of cost-effectiveness studies
In order to make different incremental cost-effectiveness
ratios (ICERs) comparable, we will convert them from
their currencies to pounds sterling (£) using purchasing
power parities [31]. Once converted to pounds sterling,
the cost data will be inflated to 2019/20 prices using the
Hospital and Community Health Services index [32]. For
studies that do not report price year, the incremental
cost-effectiveness ratios will be converted to pounds
sterling using the published year of study as the assumed
price year.
Statistical software
The analysis and presentation of results will be performed
using R (meta, netmeta and BUGSnet packages) [33–36].
Assessment of the confidence in the evidence from NMA
The confidence in the relative treatment effect estimated
in network meta-analysis for the primary outcome will be
evaluated using the Confidence in Network Meta-Analysis
framework [37], implemented in the web application. This
tool evaluates the credibility of the findings across the do-
mains of within-study bias, across-study bias, indirectness,
imprecision, heterogeneity and incoherence.
Discussion
Despite recent improvements in the burden of cardiovas-
cular disease in the UK, deaths from cardiovascular dis-
ease are relatively high compared with other high-income
countries. There is a major potential population health
impact of improving our understanding of CVD
prevention. Identifying the most effective intervention
however remains a challenge for researchers and
policymakers.
This study will provide highly relevant findings using
innovative methods to determine optimal strategies for
primary prevention of CVD. The results will be import-
ant for policymakers when making decisions between
the multiple possible alternative strategies to prevent
CVD. Compared to results from the existing multiple
separate pairwise meta-analyses, this overarching sum-
mary of all relevant work will enhance decision-making.
The findings will be crucial to inform evidence-based
priorities and guidelines for policies and planning pre-
vention strategies. The public will have answers to which
intervention or combination of interventions has the
greatest probability of being most effective and most
cost-effective in preventing CVD. Findings from our
study will inform research funders and improve the tar-
geting of subsequent research, and evaluation of add-
itional population interventions.
Given the paucity of randomised evidence on population-
wide interventions, this project will assess data from obser-
vational studies which are more prone to potential
bias. We will mitigate this by using Bayesian approach
to coherently synthesise evidence from both rando-
mised and non-randomised evidence, which will take
into account the potential bias in the observational
studies using an extra variance component.
Findings from this study will be internationally relevant.
Our findings will be widely shared with academics (as
journal articles); policymakers (such as The National Insti-
tute for Health and Care Excellence), stakeholders and key
organisations such as the British Heart Foundation (ex-
ecutive summaries) and patient groups (lay summaries).
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